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An 82-year-old female with known hypothyroidism was admitted to hospital after being found on the floor. On examination,
she was unkempt, confused, bradycardic, hypothermic, and barely arousable. Initial biochemistry revealed a thyroid stimulating
hormone (TSH) of >100mU/L and free thyroxine (FT
4
) level of 1.5 pmol/L which supported a diagnosis of myxoedema coma.
She was resuscitated and commenced on liothyronine, levothyroxine, and hydrocortisone and some improvement was made. It
became apparent that she was hiding and spitting out her oral levothyroxine including levothyroxine elixir. Given the need for
prompt alternative control, we sought advice from international experts where intramuscular levothyroxine was recommended.
She was managed from day 50 onwards with intramuscular levothyroxine 200mcg once a week, which was subsequently increased
to 500mcg. Thyroid function normalized and she made continual cognitive and physical progress and was discharged to a
rehabilitation hospital. Her intramuscular levothyroxinewas stopped and shewas subsequently restarted on oral levothyroxine, with
a plan for on-going closemonitoring of her thyroid function.This report highlights the potential to use intramuscular levothyroxine
in individuals with severe hypothyroidism arising from poor compliance with levothyroxine treatment or other potential causes
such as impaired absorption.
1. Introduction
Myxoedema coma is a rare endocrine emergency with a high
mortality rate of 25–70% [1]. It is uncommon nowadays due
to widespread thyroid function testing and a low threshold
for initiating levothyroxine therapy [2]. It has been reported
that even after 5 years of levothyroxine therapy 21.5% of indi-
viduals persist in having a TSH level>5.0mU/L [2] indicating
widespread poor compliance or malabsorption. Myxoedema
coma is more common in the winter months and in patients
with poor compliance who are already known to have
hypothyroidism [1]. Judicious use of levothyroxine, liothyro-
nine, and hydrocortisone combined with supportive care is
the mainstay of treatment for a favourable outcome.
In this paper we present an interesting case of myx-
oedema coma which was successfully managed with intra-
muscular levothyroxine as the compliance of the oral levothy-
roxine was poor. This is the first report which demonstrates
the role of intramuscular levothyroxine in the management
of myxoedema coma.
2. Case Report
An 82-year-old female was admitted in winter after being
found unresponsive. She had a history of hypothyroidism and
was prescribed levothyroxine 75𝜇g daily. Her sister reported
that over the last few months she had been increasingly tired
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Figure 1:Thyroid function tests following admission. Intramuscular
levothyroxine continued from day 50 until day 86 (end of graph)
when converted to oral levothyroxine. Unbroken vertical lines refer
to intramuscular levothyroxine initiation, dose change, and final
IM dose. Dashed vertical lines refer to dates of other intramuscular
levothyroxine injections.
and forgetful and was not compliant with her levothyroxine
tablets.
On examination, her facies were consistent with myxe-
dema and she was also found to be unkempt with evidence
of self-neglect. She was bradycardic with a heart rate of 40
beats per minute and was profoundly hypothermic with a
recorded temperature of 32.3 degrees Celsius and was barely
arousable. Initial laboratory tests revealed a thyroid stimula-
ting hormone (TSH) of >100mU/L (0.27–4.2mU/L) and free
thyroxine (FT
4
) of 1.5 pmol/L (11–25 pmol/L). She was resus-
citated with warm fluids, oxygen, and a bear hugger and was
given intravenous liothyronine and oral levothyroxine (ini-
tially via nasogastric tube) along with intravenous hydro-
cortisone in suspicion of a possibility of coexisting adrenal
suppression.
Her clinical condition gradually improved over the next
few days. Hypothermia resolved within 24 hours and her
heart rate improved over a period of 48 hours. In due course
her TSH began to normalize but her FT
4
levels remained
inconsistent (Figure 1). She was therefore maintained on
intravenous liothyronine for a longer period than that origi-
nally planned (up to day 38) as there were concerns regarding
her compliance with oral tablets even within the hospital
premises. It was highlighted by the ward nurses that she was
regularly hiding her tablets underneath her pillow or spitting
them out even if intake was tried with supervision. This was
attributed to her poor cognitive state and ongoing impaired
intellectual functioning. A further attempt was made with
levothyroxine elixir, but unfortunately it was unsuccessful as
well.
After significant deliberation and failed attempts to stabi-
lize her TFTs on oral medications we embarked on trying her
on a weekly intramuscular levothyroxine (200mcg) regime.
This resulted in more stable thyroid function (Figure 1). She
did not report any side effects from intramuscular levothy-
roxine or symptoms of thyrotoxicosis. Her thyroid function
stabilized over the next few weeks and she continued to
make significant improvement with her physical and cog-
nitive functions. Buoyed by her dramatic improvement we
increased her dose to 500mcg once a week on the 64th day
and her TFTs were repeated on a weekly basis to monitor the
change. One week later she was discharged to a community
rehabilitation hospital, where she continued to make good
progress. After almost 3 months of levothyroxine therapy,
there was a modest improvement in her cognitive state to an
extent which would sufficiently enable her to take her oral
medication more reliably. As her TFTs and clinical state were
progressing satisfactorily we stopped her intramuscular levo-
thyroxine on day 86 and oral levothyroxine was recom-
menced. Our long termplan is tomanage her with supervised
onceweekly oral dosing or consider her for once/twiceweekly
intramuscular levothyroxine therapy if her thyroid function
becomes suboptimal again.
Poor compliance with medications which ought to be
taken lifelong is a well-recognised problem [3]. Inadequate
intake of levothyroxine which is usually designed for daily
intake is reflected on TFTs with a persistently elevated TSH.
One strategy in treating such cases hypothyroidism has been
the use of once or twice weekly supervised oral therapy,
although successful studies to date have been small [4, 5]. Pre-
vious case reports have successfully demonstrated the use of
intramuscular levothyroxine therapy in patients with unchar-
acterizedmalabsorption [6], but use of parenteral levothyrox-
ine therapy has not been studied rigorously to date and there
are no well-established consensus guidelines at present [6].
Our strategy of a weekly intramuscular levothyroxine
therapy did appear to stabilize our patient’s thyroid status and
allowed her clinical and cognitive state to improve continu-
ously. It also provided us with a window of opportunity to
ensure compliance when oral preparations were proving to
be difficult. Moreover, whilst there was substantial variability
in her thyroid function, we could reliably stabilize her
TFTs without making her overtly hyperthyroid and further
detrimental effects of ongoing hypothyroidism were suitably
averted. To our knowledge this is the first time that the
intramuscular route has been used to deliver levothyroxine
in a patient with myxoedema coma. In individuals with
such profound thyroid disturbance, poor circulation with
impaired transport of intramuscular levothyroxine into the
circulationmight have been expected, but this did not appear
to be the case in our patient.
In summary this case report crucially highlights that the
intramuscular route for levothyroxine is a viable strategy even
in profound hypothyroidism and would be useful in patients
with either poor compliance or absorption. Although there
was substantial variability in FT
4
levels on IM levothyroxine
this may have been reduced by using twice weekly regime
which we would consider if she requires IM levothyroxine
again or when we encounter a similar patient.
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3. Learning Point for Clinicians
This case report highlights the potential for severe harm that
may arise due to poor compliance with thyroid hormone
replacement. It also demonstrates that intramuscular levothy-
roxine is a viable treatment even in severe hypothyroidism
and maybe particularly useful in individuals with poor
compliance due to self-neglect and cognitive impairment or
in patients with poor gastrointestinal absorption.
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